Cambrex (NASDAQ: FOLD) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Risk & Volatility

Cambrex has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Cambrex and Amicus Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambrex 0 1 2 0 2.67
Amicus Therapeutics 0 2 5 0 2.71

Cambrex currently has a consensus target price of $60.00, suggesting a potential downside of 6.90%. Amicus Therapeutics has a consensus target price of $19.67, suggesting a potential upside of 51.52%. Given Amicus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Amicus Therapeutics is more favorable than Cambrex.

Profitability

This table compares Cambrex and Amicus Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cambrex 20.75% 22.32% 16.44%
Amicus Therapeutics -460.04% -53.45% -32.85%

Earnings and Valuation

This table compares Cambrex and Amicus Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cambrex $534.46 million 4.01 $102.45 million $3.17 20.33
Amicus Therapeutics $36.93 million 66.47 -$284.00 million ($2.92) -4.45

Cambrex has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Cambrex, indicating that it is currently the more affordable of the two stocks.

Summary

Cambrex beats Amicus Therapeutics on 8 of the 12 factors compared between the two stocks.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

About Amicus Therapeutics

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.